RadNet Reports Fourth Quarter and Record Full Year 2014 Results and Releases 2015 Financial Guidance For the fourth quarter, RadNet reports Total Net Revenue ("Revenue") of $185.6 million and Adjust

RadNet Reports Fourth Quarter and Record

Full Year 2014 Results and Releases 2015 Financial Guidance

California, March 16, 2015 - RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective,

fixed-site outpatient diagnostic imaging services through a network of 259 owned and/or operated outpatient imaging centers, today

reported financial results for its fourth quarter and full year ended December 31, 2014.

Fourth Quarter Report:

For the fourth quarter of 2014, RadNet reported

Revenue of $185.6 million, Adjusted EBITDA(1) of $32.0 million and Net Income of $4.2 million. Revenue increased

$7.2 million (or 4.0%), Adjusted EBITDA(1) increased $150,000 (or 0.5%) and Net Income increased $3.0 million (or 238.3%)

over the fourth quarter of 2013.

Net Income for the fourth quarter was $0.10

per diluted share, compared to a Net Income of $0.03 per diluted share in the fourth quarter of 2013. These per share values are

based upon a weighted average number of diluted shares outstanding of 44.2 million in the fourth quarter of 2014 and 39.6 million

of diluted shares outstanding in the fourth quarter of 2013.

Affecting Net Income

in the fourth quarter of 2014 were certain non-cash expenses and non-recurring items including: $431,000 of non-cash employee stock

compensation expense resulting from the vesting of certain options and restricted stock; $265,000 of severance paid in connection

with headcount reductions related to cost savings initiatives; $468,000 gain on the disposal of certain capital equipment; and

$1.3 million of amortization of deferred financing fees and discount on issuance of debt related to

our existing credit facilities.

For the fourth quarter of 2014, as compared

with the prior year's fourth quarter, MRI volume increased 9.4%, CT volume increased 16.3% and PET/CT volume increased 3.9%.

Overall volume, taking into account routine imaging exams, inclusive of x-ray, ultrasound, mammography and other exams, increased

10.5% over the prior year's fourth quarter. On a same-center basis, including only those centers which were part of RadNet

for both the fourth quarters of 2014 and 2013, MRI volume increased 7.1%, CT volume increased 14.1% and PET/CT volume increased

3.8%. Overall same-center volume, taking into account routine imaging exams, inclusive of x-ray, ultrasound, mammography and other

exams, increased 7.3% over the prior year's same quarter.

Dr. Howard Berger, President and Chief Executive

Officer of RadNet, commented "We are very pleased with our fourth quarter performance. We had a very strong fourth quarter

last year. And despite facing significant reimbursement cuts in 2014, we were able to exceed the Revenue and EBITDA performance

of 2013's fourth quarter. This year's fourth quarter was a continuation of improved procedural volume performance and

aggressive cost containment that we experienced throughout the year. Like last year's fourth quarter, we benefited from increased

procedures from patients in large-deductive health plans who sought to utilize medical services prior to these deductibles resetting

in 2015. Also, we experienced improved patient volumes from additional enrollees in health exchanges under the Healthcare Reform

For full year 2014, the Company reported Revenue

of $717.6 million, Adjusted EBITDA(1) of $126.5 million and Net Income of $1.4 million. Revenue increased

$14.6 million (or 2.1%) and Adjusted EBITDA(1) increased $13.7 million (or 12.1%). Income Before Income Taxes (excluding

the Loss on Early Extinguishment of Senior Notes related to our refinancing transaction completed in March 2014) was $19.6 million

compared to $5.9 million in 2013. This was an increase of $13.7 million (or 233%). Net Income for 2014 (unadjusted for the $15.9

million Loss on Early Extinguishment of Senior Notes) was $0.03 per diluted share, compared to Net Income of $0.05 per diluted

share in 2013 (based upon a weighted average number of diluted shares outstanding of 43.1 million and 39.8 million in 2014 and

2013, respectively).

Affecting Net Income

in 2014 were certain non-cash expenses and non-recurring items including: $2.5 million of non-cash employee stock compensation

expense resulting from the vesting of certain options and restricted stock; $1.2 million of severance paid in connection

with headcount reductions related to cost savings initiatives; $1.1 million loss on the disposal of certain capital equipment;

and $5.7 million of amortization and write off of deferred financing fees and discount on issuance

of debt related to our existing credit facilities and refinancing transaction.

For the year ended December 31, 2014, as compared

to 2013, MRI volume increased 4.8%, CT volume increased 8.5% and PET/CT volume increased 0.4%. Overall volume, taking into account

routine imaging exams, inclusive of x-ray, ultrasound, mammography and other exams, increased 6.4% for the twelve months of 2014

Dr. Berger commented, "I'm very

proud of RadNet's accomplishments in 2014. We faced approximately $22 million of Medicare reimbursement cuts throughout 2014.

Our record Revenue and EBITDA were the result of a variety of factors including: (i) executing on a $30 million cost savings program

commenced at the beginning of the year; (ii) increased revenue from signing several new capitation contracts during the year; (iii)

larger patient volumes from state and privately run healthcare exchanges as a result of the Affordable Care act; and (iv) market

share gains within a number of our regional operating subsidiaries."

Dr. Berger added, "2014 was particularly

noteworthy for us in that it marked the first time we had any material expansion outside of the United States. We recently announced

significant contracts awarded to RadNet to provide national cancer screening services in Qatar and to provide a suite of information

technology solutions to the largest private medical center company in Israel. In conjunction with winning these contracts and

increasing RadNet's corporate marketing presence in November 2014 at the principal radiology industry convention, we expensed

investments in 2014 of over $1 million in advance of recognizing the associated revenue from these initiatives in 2015 and beyond."

Actual 2014 Results vs. 2014 Guidance:

The following compares the Company's

actual 2014 performance with previously announced revised guidance levels.

Dr. Berger commented, "I am pleased that

we met or exceeded our 2014 financial and operating guidance in virtually all categories. This was the result of great efforts

by my management team in an industry that remains challenged with reimbursement and utilization pressures. It is clear to me that

our scale and breadth of capabilities continues to distinguish RadNet as the leader in fixed site imaging. The strength of our

2014 operating results gives me confidence as we move into 2015."

2015 Fiscal Year Guidance

For its 2015 fiscal year, RadNet announces

its guidance ranges as follows:

"As reflected in our guidance, we are

optimistic about 2015. Despite pricing cuts to Medicare, which we announced last November of approximately $6 million, we are anticipating

increased Revenue, EBITDA and Free Cash Flow for 2015. We have significant growth drivers in our plan, including benefiting from

capitation contracts we signed in late 2014, revenue from our recently announced breast disease management program in the nation

of Qatar and continuing confidence about our ability to drive same-center procedural volumes. Our refinancing transaction in March

of last year will result in lower cash interest expense for 2015 and our Capital Expenditures will be lower in 2015 than in 2014

(as 2014 included approximately $12 million of one-time spending related to the purchase of equipment we were previously renting).

The combination of the lower cash interest expense and capital expenditures will increase our Free Cash Flow in 2015." added

Dr. Berger continued, "Our guidance

also incorporates what we are projecting to be a soft first quarter in 2015 due to the severe winter weather conditions that have

existed in the northeastern and mid-Atlantic parts of the United States throughout January, February and into March of this year."

Conference Call for Today

Dr. Howard Berger, President and Chief Executive

Officer, and Mark Stolper, Executive Vice President and Chief Financial Officer, will host a conference call today, at 10:30 a.m.

Eastern Standard Time. During the call, management will discuss the Company's 2014 fourth quarter and year-end results.

Conference Call Details:

Date: Monday, March 16, 2015

Time: 10:30 a.m. EST

Dial In-Number: 888-481-2844

International Dial-In Number: 719-325-2495

There will also be simultaneous and archived webcasts available

at http://public.viavid.com/index.php?id=113466

or http://www.radnet.com under the "Investors" menu

section and "News Releases" sub-menu of the website. An archived replay of the call will also be available and can